Your Occupancy Expert

Cambridge Biomedical has extensive experience in developing receptor occupancy assays in soluble proteins for pharmacodynamic studies. One example is Bruton's tyrosine kinase (Btk), an enzyme that plays an important role in B-cell receptor signaling.

Btk regulates the proliferation and survival of cancer cells in various B-cell lymphoid malignancies. We have successfully developed, optimized, and validated various ELISA based assays to determine the Btk occupancy in PBMC lysates. We are well versed in this field to produce high-quality services that meet Good Laboratory Practices (GLP) regulatory standards as stated in 21 CFR Part 58.

We have the capacity to develop receptor occupancy assays using different platforms such as colorimetric ELISA or electrochemiluminescence on the MSD technology. From point of blood sample collection to occupancy testing, we are capable of acting as a central laboratory for Phase I/II studies from sample collection kit preparation to whole blood PBMC isolation and processing and lysate sample preparation for testing.

We pride ourselves in our ability to overcome rigorous challenges.

Our assay validation process includes precision, accuracy, short- and long-term stability of analyte (endogenous and drug-bound), freeze-thaw stability, dilution, and more. Our validation process can be custom built to our client specifications and in accordance with FDA guidance on bioanalytical method validation.

For more information on target and receptor occupancy, check out our publication.

When you need a variety of platforms to develop receptor occupancy assays - be confident with Cambridge Biomedical.